Kunming Pharmaceuticals, Inc.
Clinical trials sponsored by Kunming Pharmaceuticals, Inc., explained in plain language.
Chinese pharmaceutical company producing traditional and modern medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a plant extract help calm delirium? first human trial begins Results expected Sep 2026 (estimated)
- New stroke drug shows promise in early trial Results expected Oct 2026 (estimated)
-
Could a malaria pill tame discoid lupus?
Disease control Not yet recruitingThis study tests whether dihydroartemisinin, a drug used for malaria, can help treat discoid lupus erythematosus (DLE), a chronic skin condition causing red, scaly patches. Researchers will compare two doses of the drug to a standard lupus treatment (hydroxychloroquine) in 100 ad…
Phase 2 • Sponsor: Kunming Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Could a plant extract help calm delirium? first human trial begins
Symptom relief Not yet recruitingThis early-stage study will test whether an injection of gastrodin, a compound from a traditional Chinese herb, is safe and tolerable in 54 healthy adults. Researchers will also measure how the drug moves through the body. If successful, this could lead to larger studies in patie…
Phase 1 • Sponsor: Kunming Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC